CAMBRIDGE, England & BOSTON & VILLIGEN, Switzerland--(BUSINESS WIRE)--Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based ...

Asha Therapeutics has announced its rebranding as First Atom Therapeutics ("First Atom"), marking the company's evolution as a zero-shot de novo drug design company using AI-enabled molecular design ...

In drug discovery, virtual screening is a fast and cost-effective way of narrowing down vast chemical libraries to identify the most promising hits, reducing synthesis and testing requirements while ...

A new cryo-EM center provides researchers hands-on access to advanced imaging technologies to accelerate structure-based drug discovery.

For many people, "protein" is the key element of a food order. However, beyond the preferred choice of meats or plant-based ...

When machine learning is used to suggest new potential scientific insights or directions, algorithms sometimes offer solutions that are not physically sound. Subscribe to our newsletter for the latest ...

Nuclera, the biotechnology company enabling rapid access to high-quality proteins and leadXpro, a specialist in structure-based drug discovery for membrane proteins, today announced a scientific ...

Partnership will deliver AI-guided end-to-end workflow to access challenging membrane protein targets To de-risk and shorten path to critical structural and biophysical insights that inform ...